Showing 4071-4080 of 6038 results for "".
- RepliCel's Baldness Cure Performs Well In First In-Human Trialhttps://practicaldermatology.com/news/replicels-baldness-cure-performs-well-in-first-in-human-trial/2458246/The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup ce
- Cloudy With a Chance of Wrinkles: Most Americans Fail to Protect Skin From Pollutionhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-most-americans-fail-to-protect-skin-from-pollution/2458275/Most Americans don’t protect their skin from pollutants even though they are aware of the harm that pollution and other environmental stressors can cause to skin, according to a new survey by H2O+ Beauty. Just 33 percent of people purchase
- Rumor Has It Syneron Is Next In Week of Surprising Aquisitionshttps://practicaldermatology.com/news/rumor-has-it-syneron-is-next-in-week-of-surprising-aquisitions/2458286/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- Certain Lifestyle Choices May Trump Genes When it Comes to Youthful Looking Skinhttps://practicaldermatology.com/news/certain-lifestyle-choices-may-trump-genes-when-it-comes-to-youthful-looking-skin/2458313/Nurture has a larger effect on exceptionally youthful skin appearance than nature, according to a new study by Olay done in collaboration with personal genetics company 23andMe. Specifically, sunscreen usage and
- La Roche-Posay and George Washington University Publish International Study on Sun Protection Behavior and Skin Cancer Awarenesshttps://practicaldermatology.com/news/la-roche-posay-and-george-washington-university-publish-international-study-on-sun-protection-behavior-and-skin-cancer-awareness/2458327/A large international survey on sun exposure behaviors and skin cancer detection found there are many imperfections and geographical inequalities in primary and secondary prevention of skin cancer. This information could help inform future awareness campaigns developed to address the global need
- Scleroderma Treatment Breakthrough? New Study Hints At Way To Slow Skin Fibrosishttps://practicaldermatology.com/news/scleroderma-treatment-breakthrough-new-study-suggests-way-to-slow-skin-fibrosis/2458387/New and ongoing research at Hospital for Special Surgery (HSS) in New York City has identified a possible mechanism behind the fibrosis that occurs in scleroderma – a mechanism that may one day lead to a treatment for the disease. The findings appear in the
- Doctors Welcome VOLBELLA XC for Lipshttps://practicaldermatology.com/news/doctors-welcome-volbella-xc-for-lips/2458401/Allergan’s JUVÉDERM VOLBELLA XC is here. The newly approved filler is now available for lip augmentation and correction of perioral rhytids in adults over the age of 21. Physicians can purchase VOLBELLA XC after completion of an
- Oral Nalbuphine®ER Performs Well in Phase 2 Trial of Prurigo Nodularishttps://practicaldermatology.com/news/oral-nalbuphineer-performs-well-in-from-phase-2-trial-in-prurigo-nodularis/2458403/Trevi Therapeutics, Inc.’s Oral Nalbuphine®ER reduced itch intensity and improved quality of life in prurigo nodularis patients, according to a Phase 2 Trial. Nalbuphine ER is an oral extended release mu receptor an
- Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studieshttps://practicaldermatology.com/news/regeneron-and-sanofis-ad-drug-dupilumab-performs-well-in-phase-iii-studies/2458418/Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in the New England Journal of Medicine in conjunction with a presentation at the European Ac
- New Research Suggests Why PD-1 Blockers Don't Work for All Melanoma Patientshttps://practicaldermatology.com/news/new-research-suggests-why-pd-1-blockers-dont-work-for-all-melanoma-patients/2458645/Immunotherapy using anti-PD-1 antibodies has been a game change for metastatic melanoma patients, but 60 to 70 percent of patients’ melanoma tumors are resistant to the anti-PD-1 antibodies. Now new research out of UCLA suggests that patterns of gene